SynthesisPediatrics2011
A systematic review of secretin for children with autism spectrum disorders.
Synthesis in Pediatrics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- Pharmacological intervention for irritability, aggression, and self-injury in autism spectrum disorder (ASD).The Cochrane database of systematic reviews · 2023Pooled it
- Intravenous secretin for autism spectrum disorders (ASD).The Cochrane database of systematic reviews · 2012Pooled it
- Safety and target engagement of an oral small-molecule sequestrant in adolescents with autism spectrum disorder: an open-label phase 1b/2a trial.Nature medicine · 2022Trial
- Baseline factors predicting placebo response to treatment in children and adolescents with autism spectrum disorders: a multisite randomized clinical trial.JAMA pediatrics · 2013Trial
- Cannabidiol (CBD) Treatment for Severe Problem Behaviors in Autistic Boys: A Randomized Clinical Trial.Journal of autism and developmental disorders · 2025Article
- Gene therapy as an emerging treatment forFundamental research · 2024Review
- Microbial stimulation of oxytocin release from the intestinal epithelium via secretin signaling.Gut microbes · 2023Article
- Microbial stimulation of oxytocin release from the intestinal epithelium via secretin signaling.bioRxiv : the preprint server for biology · 2023Article
- The Potential Role of Gut Peptide Hormones in Autism Spectrum Disorder.Frontiers in cellular neuroscience · 2020Review
- Reprint of: Serotonin as a link between the gut-brain-microbiome axis in autism spectrum disorders.Pharmacological research · 2019Article
- Serotonin as a link between the gut-brain-microbiome axis in autism spectrum disorders.Pharmacological research · 2018Review
- Newspaper Coverage of Autism Treatment in Canada: 10-Year Trends (2004-2013).Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2015Article
- Treating the whole person with autism: the proceedings of the Autism Speaks National Autism Conference.Current problems in pediatric and adolescent health care · 2014Review
- The central mechanisms of secretin in regulating multiple behaviors.Frontiers in endocrinology · 2014Review
- Parental perspectives on use, benefits, and physician knowledge of complementary and alternative medicine in children with autistic disorder and attention-deficit/hyperactivity disorder.Journal of alternative and complementary medicine (New York, N.Y.) · 2013Article
- The importance of autism research.Dialogues in clinical neuroscience · 2012Article
- A review of complementary and alternative treatments for autism spectrum disorders.Autism research and treatment · 2012Article
- Medical treatment overview: traditional and novel psycho-pharmacological and complementary and alternative medications.Current opinion in pediatrics · 2011Review
Corrections and comments
- Commented on by
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextAs many as 1 in every 110 children in the United States has an autism spectrum disorder (ASD). Secretin is 1 of many medical treatments studied for treating the symptoms of ASDs, but there is currently no consensus regarding which interventions are most effective.
objectiveTo systematically review evidence regarding the use of secretin in children with ASDs who are aged 12 years and younger.
methodsWe searched the Medline, PsycINFO, and ERIC (Education Resources Information Center) databases from 2000 to May 2010 and reference lists of included articles. Two reviewers independently assessed each study against predetermined inclusion/exclusion criteria. Two reviewers independently extracted data regarding participant and intervention characteristics, assessment techniques, and outcomes and assigned overall quality and strength-of-evidence ratings on the basis of predetermined criteria.
resultsEvidence from 7 randomized controlled trials supports a lack of effectiveness of secretin for the treatment of ASD symptoms including language and communication impairment, symptom severity, and cognitive and social skill deficits. No studies have resulted in significantly greater improvements in measures of language, cognition, or autistic symptoms when compared with placebo; study authors who reported improvement over time did so equally for both the intervention and placebo groups.
conclusionsSecretin has been studied extensively in multiple randomized controlled trials, and there is clear evidence that it lacks benefit. The studies of secretin included in this review uniformly point to a lack of significant impact of secretin in the treatment of ASD symptoms. Given the high strength of evidence for a lack of effectiveness, secretin as a treatment approach for ASDs warrants no further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.